Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
Minimalist illustration of a neuron and synapse in dark colors with lime accents.

Jun 23, 2026

SK Biopharm taps Insilico in $2.5B AI CNS drug discovery deal

SK Biopharmaceuticals has entered a significant collaboration with Insilico Medicine, aimed at revolutionizing CNS drug discovery through AI technologies.The partnership, valued at over $2.5 billion, was unveiled during the BIO International Convention in San Diego. This collaboration will leverage Insilico's Pharma.AI platform alongside SK Biopharm's expertise in developing and commercializing treatments for central nervous system disorders. The deal highlights the growing trend within the biop
An open laboratory notebook on a cluttered lab bench, surrounded by papers and manuals.

Jun 23, 2026

NVIDIA tools aim to turn AI agents into lab helpers for drug discovery

NVIDIA has unveiled the BioNeMo Agent Toolkit, designed to enhance the capabilities of AI agents in drug discovery and other life sciences applications.This toolkit integrates advanced tools and libraries developed over the last decade, enabling AI agents to assist scientists in various tasks such as computational experiments, data analysis, and evidence gathering. By providing domain-specific capabilities, the BioNeMo toolkit aims to streamline workflows in biology, chemistry, genomics, and dru
A vial of drug compound on a lab bench with equipment in the background.

Jun 22, 2026

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion

Insilico Medicine has entered a significant partnership with SK Biopharmaceuticals, valued at over $2.5 billion, aimed at advancing drug development for neuroimmune disorders.This collaboration will leverage Insilico's Pharma.AI platform for the design of new drug candidates, while SK Biopharmaceuticals will manage the later stages of development and commercialization. Initial payments to Insilico are set at $18 million, with the potential for the total deal value to reach $2.5 billion contingen
A vial of biologic drug on a laboratory countertop in a dimly lit setting.

Jun 22, 2026

France’s Bionyra Pharma launches with €143 million Series A to advance inflammatory disease biologics

Bionyra Pharma has officially launched with a significant €143 million ($165 million) Series A funding round, aimed at developing next-generation biologics for immune-mediated inflammatory diseases. The funding was co-led by Jeito Capital and Sofinnova Partners, with participation from several other investors, reflecting strong interest in innovative solutions for unmet medical needs in this field.The company, co-founded by former Sanofi R&D executive Dr. Frédéric Marrache, aims to address the s
Minimalist illustration of a brain with neuron connections

Jun 22, 2026

Insilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatment

Insilico Medicine has announced a significant collaboration with SK Biopharmaceuticals aimed at advancing AI-driven treatments for central nervous system (CNS) disorders. This partnership will leverage Insilico's Pharma.AI platform to discover novel drug candidates that will be further developed and commercialized by SK Biopharmaceuticals.According to SK Biopharmaceuticals' CEO, this collaboration marks a pivotal expansion into new therapeutic areas beyond epilepsy, building on their existing ex
A syringe filled with monoclonal antibody solution on a laboratory countertop.

Jun 22, 2026

TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million

TrueLab Biopharmaceutical has entered into a significant licensing agreement with Bionyra Pharma, granting Bionyra exclusive rights to develop and commercialize two innovative antibodies aimed at treating immune-mediated inflammatory diseases. The deal could be worth up to $985 million, including milestone payments and royalties.This collaboration centers on TL-001, an anti-TL1A monoclonal antibody, and TL-003, a bispecific antibody targeting TL1A and IL-23. Bionyra is now positioned to advance
A minimalist illustration of a test tube representing drug discovery.

Jun 19, 2026

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise

Charles River Laboratories has partnered with Lilly TuneLab to enhance its AI/ML drug discovery platform by leveraging nonclinical testing expertise.The collaboration aims to strengthen Charles River's client relationships while modernizing research and development through cutting-edge technologies. Lilly TuneLab, developed by Eli Lilly, provides a collaborative AI/ML platform that allows participating companies to utilize advanced drug discovery models based on extensive proprietary research da
A cell culture dish and pipette in a dimly lit lab setting, symbolizing biotechnology research.

Jun 19, 2026

Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers

Portal Biotechnologies has successfully closed an oversubscribed $9 million funding round, signaling robust growth in its cell engineering and drug discovery platform. This funding, led by NFX, will support the company's expansion in drug discovery workflows, AI data generation, and cell therapy manufacturing.With over 100 customers, including major players like Microsoft and Merck, Portal is gaining traction in the biotech landscape. Its innovative mechanoporation technology facilitates the del
A minimalist representation of a pill and a molecule in flat design.

Jun 19, 2026

Pharma-Bio Association Holds First AI Drug Discovery Advisory Committee Meeting

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association recently convened its inaugural AI Drug Discovery Advisory Committee meeting, marking a significant step in integrating artificial intelligence into drug development.Held at the Parnas Hotel in Seoul, the meeting focused on enhancing educational initiatives and promoting AI-driven drug development. Key discussions included the introduction of a comprehensive training program aimed at equipping professionals with practical skills i
A peptide sample in a lab setting

Jun 18, 2026

LG AI Research and D&D Pharmatech Join Forces to Accelerate AI-Powered Oral Peptide Drug Discovery

LG AI Research has partnered with D&D Pharmatech to push the boundaries of oral peptide drug development using AI technology.The collaboration aims to revolutionize drug discovery by integrating LG's advanced AI capabilities with D&D's expertise in peptide development. This partnership was formalized at a signing ceremony in Seoul, attended by executives from both companies. Woohyung Lim from LG AI Research emphasized that this initiative is not just about technology adoption; it represents a st
A close-up of a cell culture dish with RNA strands in a laboratory setting.

Jun 18, 2026

Portal Biotechnologies Raises $9 Million To Expand Cell Engineering Platform

Portal Biotechnologies has successfully secured $9 million in an oversubscribed financing round aimed at enhancing its cell engineering and drug discovery platform.The funding, led by NFX and supported by existing investors like IA Ventures and Pear VC, will facilitate the commercial scaling of Portal's innovative platform. This technology addresses a critical challenge in biology: the efficient delivery of complex molecules into cells without compromising their function. Portal's mechanoporatio
A syringe and vial in a dimly lit lab setting

Jun 18, 2026

Insilico Medicine to showcase AI-driven drug breakthroughs at BIO 2026 International Convention

Insilico Medicine is set to present its advancements in AI-driven drug discovery at the upcoming BIO 2026 International Convention in San Diego, scheduled for June 22-25. The company aims to engage with biopharma partners and researchers, showcasing its Pharma.AI platform alongside its R&D pipeline.Dr. Alex Zhavoronkov, the company's founder and CEO, will deliver four significant presentations during the event. These will cover a range of topics, including the impact of AI on drug development, i